ArticleCancer cell2014
Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05120284 (Trial of Dichloroacetate), which is not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Who cites it
53 citing papers in PubMed, 86 citations in OpenAlex.
- Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.The Lancet. Oncology · 2019Trial
- Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas.Nature communications · 2025Article
- Lactate Metabolism in Health and Disease.Advances in experimental medicine and biology · 2025Review
- Quantifying Spatiotemporal Heterogeneity of Tumor Metabolism and Vasculature with a Multiparametric Point-of-Investigation Microscope.BME frontiers · 2025Article
- ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs.Cancer research · 2024Article
- Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas.Disease models & mechanisms · 2024Review
- An endothelial-related prognostic index for bladder cancer patients.Discover oncology · 2024Article
- Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS).Medical oncology (Northwood, London, England) · 2024Article
- ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97.Nature communications · 2024Article
- Advances in treatment of alveolar soft part sarcoma: an updated review.Japanese journal of clinical oncology · 2023Review
- Imaging Features of Alveolar Soft Part Sarcoma: Single Institution Experience and Literature Review.Clinics and practice · 2023Article
- TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer.International journal of cancer · 2023Article
- ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma.Nature communications · 2023Article
- Emerging roles of TFE3 in metabolic regulation.Cell death discovery · 2023Review
- Review
- On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.International journal of molecular sciences · 2022Review
- Lactate receptor HCAR1 regulates cell growth, metastasis and maintenance of cancer‑specific energy metabolism in breast cancer cells.Molecular medicine reports · 2022Article
- Effects of Low-Intensity and Long-Term Aerobic Exercise on the Psoas Muscle ofInternational journal of molecular sciences · 2022Article
- Monocarboxylate Transporter 4 in Cancer-Associated Fibroblasts Is a Driver of Aggressiveness in Aerodigestive Tract Cancers.Frontiers in oncology · 2022Article
- Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Alveolar soft part sarcoma (ASPS), a deadly soft tissue malignancy with a predilection for adolescents and young adults, associates consistently with t(X;17) translocations that generate the fusion gene ASPSCR1-TFE3. We proved the oncogenic capacity of this fusion gene by driving sarcomagenesis in mice from conditional ASPSCR1-TFE3 expression. The completely penetrant tumors were indistinguishable from human ASPS by histology and gene expression. They formed preferentially in the anatomic environment highest in lactate, the cranial vault, expressed high levels of lactate importers, harbored abundant mitochondria, metabolized lactate as a metabolic substrate, and responded to the administration of exogenous lactate with tumor cell proliferation and angiogenesis. These data demonstrate lactate's role as a driver of alveolar soft part sarcomagenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.